10,384 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Barclays PLC

Barclays PLC acquired a new stake in shares of Korro Bio, Inc. (NASDAQ:KRRO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,384 shares of the company’s stock, valued at approximately $395,000. Barclays PLC owned 0.11% of Korro Bio at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KRRO. Raymond James Financial Inc. bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $394,000. Legal & General Group Plc increased its position in Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock valued at $165,000 after acquiring an additional 3,759 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Korro Bio by 17.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 57,978 shares of the company’s stock valued at $2,207,000 after acquiring an additional 8,527 shares during the period. Bank of Montreal Can purchased a new stake in shares of Korro Bio in the fourth quarter valued at $217,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Korro Bio by 32.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock worth $129,000 after acquiring an additional 831 shares during the last quarter. 13.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

KRRO has been the topic of a number of recent analyst reports. Chardan Capital started coverage on shares of Korro Bio in a research report on Wednesday, April 16th. They issued a “buy” rating and a $25.00 price objective on the stock. HC Wainwright decreased their price target on Korro Bio from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday. Royal Bank of Canada cut their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 19th. Oppenheimer initiated coverage on Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 target price for the company. Finally, Cantor Fitzgerald upgraded shares of Korro Bio to a “strong-buy” rating in a report on Tuesday, April 29th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Korro Bio presently has an average rating of “Buy” and an average price target of $112.75.

Korro Bio Price Performance

KRRO stock opened at $15.56 on Friday. Korro Bio, Inc. has a 1-year low of $11.13 and a 1-year high of $98.00. The business has a 50-day moving average price of $17.78 and a 200 day moving average price of $34.55. The company has a market capitalization of $146.12 million, a P/E ratio of -1.65 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $0.11. The business had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts anticipate that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).